iCAD Inc (NASDAQ:ICAD) – Equities researchers at Zacks Investment Research lowered their FY2021 earnings estimates for iCAD in a report issued on Monday, August 12th. Zacks Investment Research analyst B. Marckx now forecasts that the technology company will post earnings per share of $0.26 for the year, down from their prior forecast of $0.31.
iCAD (NASDAQ:ICAD) last posted its earnings results on Thursday, August 1st. The technology company reported ($0.09) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.10) by $0.01. The business had revenue of $7.33 million for the quarter, compared to analysts’ expectations of $6.69 million. iCAD had a negative net margin of 43.88% and a negative return on equity of 69.95%.
Separately, ValuEngine cut shares of iCAD from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st.
NASDAQ ICAD opened at $6.25 on Wednesday. The stock has a market cap of $119.23 million, a P/E ratio of -16.45 and a beta of 1.18. The company’s 50-day simple moving average is $6.47 and its 200 day simple moving average is $5.65. iCAD has a twelve month low of $2.42 and a twelve month high of $7.45. The company has a quick ratio of 1.33, a current ratio of 1.47 and a debt-to-equity ratio of 2.90.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC acquired a new position in shares of iCAD during the second quarter worth approximately $54,000. Worth Venture Partners LLC bought a new stake in iCAD in the second quarter valued at approximately $92,000. Spark Investment Management LLC bought a new stake in iCAD in the first quarter valued at approximately $185,000. Deutsche Bank AG increased its stake in iCAD by 33.5% in the fourth quarter. Deutsche Bank AG now owns 35,923 shares of the technology company’s stock valued at $132,000 after purchasing an additional 9,023 shares in the last quarter. Finally, United Capital Financial Advisers LLC increased its stake in iCAD by 6.7% in the second quarter. United Capital Financial Advisers LLC now owns 57,765 shares of the technology company’s stock valued at $368,000 after purchasing an additional 3,625 shares in the last quarter. 18.64% of the stock is currently owned by institutional investors and hedge funds.
iCAD, Inc provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy.
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.